Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy

Next Previous
Trial Profile

First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABD 3001 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Acronyms ODYSSEY
  • Sponsors Advanced BioDesign

Most Recent Events

  • 02 Jun 2025 According to an Advanced Biodesign media release, Interim results will be presented at Europe's premier hemalogy event, the 2025 European Hematology Association (EHA) Congress, highlighting the global relevance of these findings.
  • 27 May 2025 According to an Advanced Biodesign media release, today announced positive interim results from the Safety Review Committee (SRC) for the second part of the Phase 1 ODYSSEY clinical trial.
  • 04 Mar 2025 According to an Advanced Biodesign media release, the first patient has been successfully treated for 3 cycles of treatment in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top